NYSE:WAT - Waters Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $193.50 -4.59 (-2.32 %) (As of 07/16/2018 04:00 PM ET)Previous Close$198.09Today's Range$190.73 - $194.9852-Week Range$171.32 - $220.20Volume715,000 shsAverage Volume558,327 shsMarket Capitalization$15.52 billionP/E Ratio25.96Dividend YieldN/ABeta0.96 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Waters Corporation, a specialty measurement company, provides analytical workflow solutions in the United States, Europe, Asia, and internationally. It designs, manufactures, sells, and services high and ultra performance liquid chromatography technology, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. The company also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. In addition, the company offers thermal analysis, rheometry, and calorimetry instruments, which are used in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for use in various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts. Receive WAT News and Ratings via Email Sign-up to receive the latest news and ratings for WAT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorComputer and Technology SymbolNYSE:WAT CUSIP94184810 Webwww.waters.com Phone508-478-2000 Debt Debt-to-Equity Ratio0.59 Current Ratio6.44 Quick Ratio5.87 Price-To-Earnings Trailing P/E Ratio25.96 Forward P/E Ratio23.57 P/E Growth2.31 Sales & Book Value Annual Sales$2.31 billion Price / Sales6.56 Cash Flow$8.7162 per share Price / Cash22.20 Book Value$28.09 per share Price / Book6.89 Profitability EPS (Most Recent Fiscal Year)$7.49 Net Income$20.31 million Net Margins1.14% Return on Equity25.80% Return on Assets12.27% Miscellaneous Employees7,000 Outstanding Shares78,340,000Market Cap$15,518.96 Waters (NYSE:WAT) Frequently Asked Questions What is Waters' stock symbol? Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT." How will Waters' stock buyback program work? Waters declared that its board has authorized a share repurchase plan on Tuesday, April 24th 2018, which permits the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 18.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board believes its shares are undervalued. How were Waters' earnings last quarter? Waters Co. (NYSE:WAT) issued its earnings results on Tuesday, April, 24th. The medical instruments supplier reported $1.59 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.55 by $0.04. The medical instruments supplier had revenue of $530.70 million for the quarter, compared to the consensus estimate of $534.17 million. Waters had a return on equity of 25.80% and a net margin of 1.14%. The business's revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the company earned $1.46 EPS. View Waters' Earnings History. When is Waters' next earnings date? Waters is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Waters. What guidance has Waters issued on next quarter's earnings? Waters updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $8.10-8.30 for the period, compared to the Thomson Reuters consensus estimate of $8.19. What price target have analysts set for WAT? 16 analysts have issued 12 month price objectives for Waters' shares. Their predictions range from $180.00 to $230.00. On average, they expect Waters' stock price to reach $206.1429 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price. View Analyst Ratings for Waters. What is the consensus analysts' recommendation for Waters? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 9 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Waters' key competitors? Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Integra Lifesciences (IART), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM) and Harvard Bioscience (HBIO). Who are Waters' key executives? Waters' management team includes the folowing people: Mr. Christopher James O'Connell, Chairman & CEO (Age 51)Ms. Sherry L. Buck, Sr. VP & CFO (Age 54)Dr. Michael C. Harrington, Sr. VP of Global Markets (Age 57)Mr. Ian S. King, Sr. VP of Global Products (Age 61)Mr. Eugene G. Cassis, Sr. Advisor (Age 61) Has Waters been receiving favorable news coverage? News headlines about WAT stock have been trending somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Waters earned a news impact score of 0.15 on Accern's scale. They also gave media coverage about the medical instruments supplier an impact score of 46.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are Waters' major shareholders? Waters' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fenimore Asset Management Inc. (0.37%), Bank of Montreal Can (0.11%), Copper Rock Capital Partners LLC (0.08%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%), State of Alaska Department of Revenue (0.02%) and Denali Advisors LLC (0.02%). Company insiders that own Waters stock include Arthur G Caputo, Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters. Which institutional investors are selling Waters stock? WAT stock was sold by a variety of institutional investors in the last quarter, including NN Investment Partners Holdings N.V., State of Alaska Department of Revenue, Fenimore Asset Management Inc., Copper Rock Capital Partners LLC, Gateway Investment Advisers LLC and Raymond James Trust N.A.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters. Which institutional investors are buying Waters stock? WAT stock was bought by a variety of institutional investors in the last quarter, including DnB Asset Management AS, Bank of Montreal Can, Denali Advisors LLC, Fjarde AP Fonden Fourth Swedish National Pension Fund, IFM Investors Pty Ltd, Pennsylvania Trust Co and Ledyard National Bank. View Insider Buying and Selling for Waters. How do I buy shares of Waters? Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Waters' stock price today? One share of WAT stock can currently be purchased for approximately $193.50. How big of a company is Waters? Waters has a market capitalization of $15.52 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe. How can I contact Waters? Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected] MarketBeat Community Rating for Waters (NYSE WAT)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 311 (Vote Outperform)Underperform Votes: 417 (Vote Underperform)Total Votes: 728MarketBeat's community ratings are surveys of what our community members think about Waters and other stocks. Vote "Outperform" if you believe WAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?